Bionano Genomics
BNGOPre-clinicalBionano Genomics is on a mission to transform the way the world sees the genome through its optical genome mapping technology, which detects structural variants missed by traditional cytogenetics and sequencing. The company has commercialized its OGM systems and software, with over 500 publications citing its use in research and clinical applications. Bionano's strategic focus is on driving adoption in clinical cytogenomics and research labs to improve the diagnosis and understanding of cancers and genetic diseases.
BNGO · Stock Price
Historical price data
AI Company Overview
Bionano Genomics is on a mission to transform the way the world sees the genome through its optical genome mapping technology, which detects structural variants missed by traditional cytogenetics and sequencing. The company has commercialized its OGM systems and software, with over 500 publications citing its use in research and clinical applications. Bionano's strategic focus is on driving adoption in clinical cytogenomics and research labs to improve the diagnosis and understanding of cancers and genetic diseases.
Technology Platform
Optical Genome Mapping (OGM) technology that linearizes and images ultra-high molecular weight DNA to detect structural variants (SVs) across the entire genome, complementing next-generation sequencing.
Funding History
5Opportunities
Risk Factors
Competitive Landscape
Bionano competes with traditional cytogenetics methods (Abbott, OpGen), chromosomal microarray (Thermo Fisher, Agilent), and next-generation sequencing giants (Illumina, PacBio, Oxford Nanopore). Its differentiation is a specialized, high-throughput platform optimized for genome-wide structural variant detection, positioned as a complementary tool to NGS.